Dendritic cell-based vaccine(Baylor Research Institute)(Dendritic cell-based vaccine(Baylor Research Institute))

概要

基本信息

药物类型

预防性疫苗、树突状细胞疫苗

别名

DC-HIV LIPO-5

靶点-

作用机制-

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

Baylor Research Institute

在研机构-

非在研机构

Baylor Research InstituteEl Paso ANRS Investments LLC

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Dendritic cell-based vaccine(Baylor Research Institute) 相关的临床试验

JPRN-UMIN000009424 / CompletedN/AIIT

Clinical trial of cellular immunotherapy for malignant tumor (cancer immunotherapy with dendritic cell-based vaccines) - Cancer immunotherapy with dendritic cell-based vaccines

开始日期2012-11-12

申办/合作机构-

EUCTR2009-017259-91-CZ / Not yet recruitingN/AIIT

Phase I/II clinical trial: Immunotherapy of prostate cancer patients in biochemical relapse with dendritic cell-based vaccine - Imunoterapie karcinomu prostaty dendritickými bunkami

开始日期2010-03-10

申办/合作机构-

EUCTR2009-017295-24-CZ / Not yet recruitingN/AIIT

Phase I/II clinical trial:Immunotherapy of hormone-refractory prostate cancer patients with dendritic cell-based vaccine (Fáze I/II klinické studie imunoterapie hormonálne refrakterního karcinomu prostaty pomocí vakcinace dendritickými bunkami) - Imunoterapie karcinomu prostaty dendritickými bunkami

开始日期2010-03-10

申办/合作机构-

100 项与 Dendritic cell-based vaccine(Baylor Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Dendritic cell-based vaccine(Baylor Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Dendritic cell-based vaccine(Baylor Research Institute) 相关的专利（医药）

登录后查看更多信息

80

项与 Dendritic cell-based vaccine(Baylor Research Institute) 相关的文献（医药）

2024-12-31·Human Vaccines & Immunotherapeutics

Bibliometric analysis of dendritic cell-based vaccines over the past 15 years

Article

作者: Wu, Yinghua ; Liu, Bo ; Long, Zhi ; Lu, Jiping ; Zhong, Liangchen

Dendritic cells, which are crucial for inducing T-cell responses, are pivotal in current immunotherapy strategies aiming to replenish depleted T cells within the tumor microenvironment to combat tumors. Consequently, dendritic cell vaccine-based cancer therapies have garnered significant attention. Through bibliometric analysis, we examined research trends in this field. We searched the Web of Science core database and identified 16,476 articles on dendritic cell-based vaccines published from January 1, 2009, to December 30, 2023. The United States leads in this research domain, with Emory University being a prominent collaborator. The Journal of Immunology is the primary publication outlet, and Banchereau, J emerges as the most influential author. Recent hot keywords include nanoparticle, delivery, cancer vaccine, and clinical trial, indicating that cancer immunotherapy research, especially dendritic cell-based vaccines, is poised to become a future trend and hotspot.

2023-08-01·Anticancer Research

Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma

Review

作者: Sun, Chong ; Zhou, Chuanli ; Guo, Jianwei ; Zhang, Zhuoli ; Ma, Xuexiao

Osteosarcoma is the most common primary bone malignancy, and surgical resection combined with neoadjuvant chemotherapy is the gold-standard treatment for affected patients. Although the overall survival rates for patients with osteosarcoma currently range from 60% to 70%, outcomes remain disappointing for patients with recurrent, metastatic, or unresectable disease. Irreversible electroporation (IRE) is a novel ablation technique with the potential to elicit an immune response in solid tumors. Dendritic cell (DC)-based tumor vaccines have shown promising therapeutic efficacy in preclinical studies focused on osteosarcoma; however, only limited therapeutic efficacy has been observed in clinical trials. Thus, there is considerable potential therapeutic value in developing combination osteosarcoma treatments that involve IRE and DC-based tumor vaccines. In this review, we discuss recent advances in preclinical and clinical DC-based immunotherapies, as well as potential combinations of DC-based vaccines and IRE, that may improve therapeutic outcomes for patients with osteosarcoma.

2023-01-18·ACS Chemical Neuroscience

Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy

Article

作者: Vedam-Mai, Vinata ; Hall, Jesse ; Gurrala, Anjela ; Flores, Catherine T. ; Okun, Michael S. ; Raman, Shreya ; Becsey, Alexander ; Chu, Winston T. ; Vaillancourt, David E. ; Giasson, Benoit I.

Aggregated α-synuclein, a major constituent of Lewy bodies plays a crucial role in the pathogenesis of α-synucleinopathies (SPs) such as Parkinson's disease (PD). PD is affected by the innate and adaptive arms of the immune system, and recently both active and passive immunotherapies targeted against α-synuclein are being trialed as potential novel treatment strategies. Specifically, dendritic cell-based vaccines have shown to be an effective treatment for SPs in animal models. Here, we report on the development of adoptive cellular therapy (ACT) for SP and demonstrate that adoptive transfer of pre-activated T-cells generated from immunized mice can improve survival and behavior, reduce brain microstructural impairment via magnetic resonance imaging (MRI), and decrease α-synuclein pathology burden in a peripherally induced preclinical SP model (M83) when administered prior to disease onset. This study provides preclinical evidence for ACT as a potential immunotherapy for LBD, PD and other related SPs, and future work will provide necessary understanding of the mechanisms of its action.

100 项与 Dendritic cell-based vaccine(Baylor Research Institute) 相关的药物交易

登录后查看更多信息